CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (www.dicerna.com), a second generation RNA interference company developing novel therapeutics utilizing proprietary Dicer Substrate Technology™, announced today a paper appearing in the advance online publication of Molecular Therapy which describes the therapeutic potential for Dicer-substrate small interfering RNAs (DsiRNAs) in the treatment of rheumatoid arthritis in a murine model of arthritis.
